Lancaster

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Asthma2 trials
• Fatty liver disease (MASLD/MASH)2 trials
• Irritable bowel syndrome1 trial
• Liver cirrhosis1 trial

Phase

• Phase 23 trials
• Phase 32 trials

Status

• Completed3 trials
• Recruiting2 trials

Lead sponsor

• GlaxoSmithKline5 trials

Running trials

• Recruiting

  A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)

  NCT07519395· Phase 2· GlaxoSmithKline· Source

  Contact: Kumaravel Perumalsamy (principal investigator)

• Recruiting

  A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

  NCT06920043· Phase 2· GlaxoSmithKline· Source

  Contact: Jatinder Pruthi (principal investigator)

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)1 recruiting
• Irritable bowel syndrome1 recruiting
• Liver cirrhosis1 recruiting

Closed trials

• Completed

  Phase 2b Study of GSK4532990 in Adults With NASH

  NCT05583344· Phase 2· GlaxoSmithKline· Source

• Completed

  An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

  NCT05243680· Phase 3· GlaxoSmithKline· Source

• Completed

  A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

  NCT04718103· Phase 3· GlaxoSmithKline· Source